- Home
- ALPS vs AGEN Comparison
ALPS vs AGEN Comparison
Compare ALPS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALPS | AGEN |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.5M | 126.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | ALPS | AGEN |
|---|---|---|
| Price | $1.02 | $3.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 178.9K | ★ 580.9K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,371,037.00 | ★ $106,829,000.00 |
| Revenue This Year | N/A | $67.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 40.25 | N/A |
| 52 Week Low | $0.56 | $1.38 |
| 52 Week High | $15.00 | $7.34 |
Technical Indicators
Market Signals| Indicator | ALPS | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 31.44 |
| Support Level | N/A | $3.01 |
| Resistance Level | N/A | $4.00 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 0.00 | 36.95 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).